BioNTech’s Virtual AGM Clears Path for Oncology Pivot as €16.8 Billion Cash Cushion Buys Time

Shareholders back capital authorization, board enlargement, and profit transfer as BioNTech transforms from COVID vaccine maker to oncology leader with €16.8B cash runway.

Shareholders at BioNTech’s virtual annual general meeting on Wednesday voted on a suite of structural changes designed to accelerate the company’s transformation from a pandemic-era vaccine maker into a dedicated oncology powerhouse. The centerpiece of the agenda was a new authorized capital mandate of up to €129.5 million, representing roughly half of the current share capital, which will give management the flexibility to issue new shares until 2030.

The capital authorization is paired with a planned expansion of the supervisory board from six to eight members. Three existing directors are standing for re-election, and two new specialists in oncology and clinical development will join the board, underscoring the strategic shift toward cancer therapies. Investors also approved a profit-and-loss transfer agreement with the newly formed subsidiary BioNTech Discovery GmbH, which consolidates the founders’ control over mRNA research.

The moves come during a financially turbulent period. BioNTech reported first-quarter 2026 revenue of €118.1 million, down sharply from the COVID-vaccine boom years, and a net loss of €531.9 million — equivalent to $622.3 million — driven by heavy investment in its oncology pipeline. Despite the red ink, the company’s balance sheet remains a formidable asset: liquid assets and marketable securities stood at €16.8 billion at the end of March.

That cash pile offers a multiyear runway for the expensive rebuild. BioNTech is closing several manufacturing sites in Germany and Singapore, targeting annual cost savings of €500 million that will be redirected into cancer research. The company also secured authorization to repurchase up to $1 billion of American Depositary Shares, a program intended primarily to cover equity-based compensation rather than deliver short-term shareholder returns.

The stock has struggled to reflect those fundamentals. BioNTech shares traded at €76.60 on Wednesday, down 2.67% on the day, and have fallen roughly 5% since the start of the year. The current price sits well below the 52-week high of nearly €102. Analysts see a disconnect. Berenberg lowered its price target from $155 to $140 but maintained a “Buy” rating, calling the stock “deeply undervalued.” Analyst Harry Gillis pointed to the buyback authorization and the pipeline’s potential as catalysts.

Management sees 2026 as a crucial year for data readouts. First regulatory filings for the bispecific antibody Pumitamig are expected by year-end, targeting breast and lung cancer in multiple pivotal trials. Another candidate, Gotistobart, has already demonstrated a significant reduction in mortality risk in a Phase 3 lung cancer study. Additional late-stage data from immunomodulators, antibody-drug conjugates, and mRNA cancer therapies are anticipated in the coming months.

BioNTech has maintained its full-year 2026 revenue guidance of €2.0–€2.3 billion, signaling that the core COVID franchise, while diminished, still provides a baseline. The retained earnings from 2025 will be carried forward, with no dividend payout in sight as capital is channeled into R&D and operational flexibility.

The agenda also included a vote to extend the option for virtual shareholder meetings, reinforcing the company’s push for streamlined governance. The broader message from the AGM is clear: BioNTech is betting its future on oncology, and the financial and structural pieces are being put in place to see that bet through. The next test will come not from the ballot box, but from the clinic.